Market Place
Sourcing Support
Abeona Therapeutics Reports Q3 2024 Results & Updates
14 Nov 2024 //
GLOBENEWSWIRE
Abeona Therapeutics to Participate in November Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Abeona Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
01 Nov 2024 //
GLOBENEWSWIRE
Abeona Completes Pz-cel Biologics License Resubmission to FDA
29 Oct 2024 //
GLOBENEWSWIRE
Abeona Announces New Inducement Grants Under Nasdaq LR 5635(c)(4)
01 Oct 2024 //
GLOBENEWSWIRE
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Abeona Announces New Employee Inducement Grants Under Nasdaq Listing Rule
02 Sep 2024 //
GLOBENEWSWIRE
Abeona Appoints Bernhardt Zeiher And Eric Crombez To Board Of Directors
14 Aug 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Favorable Medicare Decisions For Pz-cel
13 Aug 2024 //
GLOBENEWSWIRE
Abeona Reports Q2 2024 Results, Concludes FDA Meeting On Pz-cel BLA
12 Aug 2024 //
GLOBENEWSWIRE
Abeona Announces New Employee Inducement Grants
01 Aug 2024 //
GLOBENEWSWIRE
Abeona And Beacon To Evaluate AAV204 Capsid For Ophthalmology Use
11 Jul 2024 //
GLOBENEWSWIRE
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
08 Jul 2024 //
GLOBENEWSWIRE
Abeona Announces New Employee Inducement Grants Under Nasdaq Rules
03 Jun 2024 //
GLOBENEWSWIRE
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
28 May 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Q1 2024 Financials, Corporate Progress
15 May 2024 //
GLOBENEWSWIRE
Abeona Announces New Employee Inducement Grants
07 May 2024 //
GLOBENEWSWIRE
Abeona Prices $75M Common Stock, Pre-Funded Warrants Offering
03 May 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Provides Regulatory Update on Pz-cel
22 Apr 2024 //
GLOBENEWSWIRE
Abeona shares tumble as FDA declines to approve skin disorder treatment
22 Apr 2024 //
REUTERS
Abeona Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Full Year 2023 Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Abeona’s Form 483 is manufacturing setback for rare skin condition asset
18 Mar 2024 //
ENDPTS
Abeona Announces Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Mar 2024 //
GLOBENEWSWIRE
Abeona Announces Progress Update on Pz-cel Biologics License Application (BLA)
01 Feb 2024 //
GLOBENEWSWIRE
Abeona Announces Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Announces $50 Million Credit Facility
08 Jan 2024 //
GLOBENEWSWIRE
Abeona Announces Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Dec 2023 //
GLOBENEWSWIRE
Abeona Announces FDA Accepts and Grants Priority Review for Pz-cel BLA
27 Nov 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Abeona Announces Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Submits BLA to U.S. FDA Seeking Priority Review of EB-101
26 Sep 2023 //
GLOBENEWSWIRE
Abeona Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
12 Sep 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
07 Sep 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101
30 Aug 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Abeona Announces Submission of Briefing Package for BLA Meeting with FDA
28 Jul 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Joins Rare Disease Company Coalition
19 Jul 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering
07 Jul 2023 //
GLOBENEWSWIRE
Abeona Announces $25M Registered Direct Offering Priced Under Nasdaq Rules
03 Jul 2023 //
GLOBENEWSWIRE
FDA wants more data from Abeona Therapeutics as it pushes for BLA
10 Jun 2023 //
ENDPTS
Abeona Therapeutics Announces Regulatory Update on BLA for EB-101
09 Jun 2023 //
GLOBENEWSWIRE
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio
22 May 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces New Data from its AAV Ophthalmology Program
16 May 2023 //
GLOBENEWSWIRE
Abeona Announces Additional Phase 3 VIITAL Study Results for EB-101 Presented
11 May 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Abeona Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program
10 Apr 2023 //
GLOBENEWSWIRE
Abeona Reports Full Year 2022 Financial Results and Provides Corporate Update
29 Mar 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces New Employee Inducement Grants
24 Mar 2023 //
GLOBENEWSWIRE
Abeona Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results
16 Mar 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
14 Mar 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Abeona Therapeutics Announces $35 Million Private Placement Financing
03 Nov 2022 //
GLOBENEWSWIRE
Abeona Announces Positive Topline Results with Both Co-Primary Endpoints
03 Nov 2022 //
GLOBENEWSWIRE
Abeona to submit cell therapy for approval after +VE results for skin disorder
03 Nov 2022 //
BIOPHARMADIVE
Abeona Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101
19 Oct 2022 //
GLOBENEWSWIRE
Abeona Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL
04 Oct 2022 //
GLOBENEWSWIRE
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine
22 Sep 2022 //
GLOBENEWSWIRE
Abeona to Participate in the Cantor Fitzgerald Cell and Genetic Medicines
13 Sep 2022 //
GLOBENEWSWIRE
